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Arsenite exposure suppresses 
adipogenesis, mitochondrial 
biogenesis and thermogenesis 
via autophagy inhibition in brown 
adipose tissue
Jiyoung Bae1,2, Yura Jang1,3, Heejeong Kim1, Kalika Mahato1, cameron Schaecher1,4, 
isaac M. Kim1, eunju Kim5 & Seung-Hyun Ro  1
Arsenite, a trivalent form of arsenic, is an element that occurs naturally in the environment. Humans are 
exposed to high dose of arsenite through consuming arsenite-contaminated drinking water and food, 
and the arsenite can accumulate in the human tissues. Arsenite induces oxidative stress, which is linked 
to metabolic disorders such as obesity and diabetes. Brown adipocytes dissipating energy as heat have 
emerging roles for obesity treatment and prevention. therefore, understanding the pathophysiological 
role of brown adipocytes can provide effective strategies delineating the link between arsenite exposure 
and metabolic disorders. Our study revealed that arsenite significantly reduced differentiation of murine 
brown adipocytes and mitochondrial biogenesis and respiration, leading to attenuated thermogenesis 
via decreasing UCP1 expression. Oral administration of arsenite in mice resulted in heavy accumulation 
in brown adipose tissue and suppression of lipogenesis, mitochondrial biogenesis and thermogenesis. 
Mechanistically, arsenite exposure significantly inhibited autophagy necessary for homeostasis of 
brown adipose tissue through suppression of Sestrin2 and ULK1. These results clearly confirm the 
emerging mechanisms underlying the implications of arsenite exposure in metabolic disorders.
Obesity is a significant risk factor for several prevalent diseases, such as diabetes, hypertension, cardiovascular 
diseases, and cancers1–4. White adipose tissue (WAT) and brown adipose tissue (BAT) are the main types of adi-
pose tissue in humans5. In contrast to WAT’s functions for energy storage, BAT is specialized to produce ATP 
through enriched intracellular mitochondria and heat through non-shivering thermogenesis via the uncoupling 
protein 1 (UCP1)6–9. UCP1 proteins are localized in the inner membrane of brown adipocyte mitochondria to 
uncouple ATP synthesis from respiration10–13. While BAT quickly regresses following birth5,14, new evidence has 
revealed symmetrical fat depots in adults that have classic BAT features15–18. Therefore, BAT has become a novel 
target for obesity treatment and prevention.
Arsenite, a most potent trivalent form of arsenic, is presented in water, soil, and foods due to its abundance in 
earth crust and the use of arsenite-contaminated pesticides and insecticides19. Arsenite is accumulated in various 
tissues and organs including adipose tissues, lung, heart, kidney, brain, eye, liver, hair, bone, and spleen20–22. Thus, 
arsenite contaminated drinking water has been considered as a contributing factor for numerous health con-
cerns in humans such as diabetes, lung and skin diseases, and cancer23–25. Recent evidence suggests that exposure 
to arsenite may lead to adipose tissue dysfunction and lipodystrophy as well as inhibition of adipogenesis26,27. 
Arsenite inhibits adipogenesis and adipocyte function in human mesenchymal stem cells28, 3T3-L1 preadipo-
cytes29, and C3H 10T1/2 preadipocytes30. The mechanisms underlying adipose tissue dysfunction and inhibition 
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of adipogenesis by arsenite have been the focus of intense research. Recent studies suggest that arsenite-induced 
lipolysis is mediated through transcriptional factors, including peroxisome proliferator-activated receptor-gamma 
(PPARγ) and CCAAT-enhancer binding protein alpha (C/EBPα)28,29, as well as β-adrenergic receptor signaling31.
Autophagy is a delicate cellular recycling process in response to environmental and genotoxic stresses, which 
digests damaged proteins and organelles as a defense mechanism32. Mechanistically known so far, AMPK posi-
tively regulates autophagy induction through phosphorylating and activating ULK1, mammalian homologue of 
autophagy kinase Atg1, at Ser317, Ser555, and Ser777 whereas mTORC1 inhibits autophagy induction through 
phosphorylating and inhibiting ULK1 at Ser75733–36. ULK1 regulates downstream autophagosome receptors and 
autophagosome maturation proteins such as p6237 and LC3B, a mammalian homologue of autophagy-related 
gene (Atg) 838. Recent studies have shown that autophagy plays an important role in 3T3-L1 adipogenesis and 
lipid metabolism. Autophagy deficient 3T3-L1 preadipocytes block differentiation into mature adipocytes39. 
Moreover, Atg5 or Atg7 deficient primary mouse embryonic fibroblasts (MEF) impair adipogenesis, and auto-
phagy inhibitor, such as bafilomycin A1 and chloroquine, blocks primary MEF differentiation40,41.
Despite arsenite-induced defect in adipogenesis and fat accumulation in WAT, the roles of arsenite in reg-
ulating the functions of BAT remain to be elucidated. Here, we report the impacts of arsenite exposure on the 
functions and activities of brown adipocytes and BAT. In cultured brown adipocytes, arsenite treatment reduced 
adipogenesis, mitochondrial biogenesis, respiration and thermogenesis. Arsenite exposure in live mice resulted in 
heavy arsenic accumulation in BAT but not in WAT. Accumulated arsenite suppressed lipogenesis, mitochondrial 
biogenesis and thermogenesis in BAT. Autophagy activity was significantly reduced by arsenite exposure through 
inhibition of Sestrin2 and ULK1. Our data provides the novel mechanisms underlying the effects of arsenite 
exposure on the physiological functions of BAT and reveals the significance of autophagy in protection against 
arsenite-induced damage in BAT.
Results
Arsenite suppresses HIB1B brown adipocyte differentiation. To investigate the effects of arsenite on 
brown adipocyte differentiation, immortalized HIB1B brown preadipocytes were differentiated in the presence 
of various doses of arsenite (1–10 μM) or the vehicle control. Arsenite dose-dependently suppressed brown adi-
pocyte lipid accumulation, as revealed by Oil Red O stained multiocular, lipid-filled brown adipocytes (Fig. 1A). 
10 μM of arsenite treatment decreased brown adipocyte differentiation upto 82% (Fig. 1B). Upto 10 μM of arsen-
ite did not affect cell viability confirmed by MTT assays for upto 6 days (Fig. S1). mRNA expression of brown 
adipocyte specific markers, uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor-gamma 
coactivator 1 (PGC1), peroxisome proliferator activator receptor gamma (PPARγ), and PR domain containing 16 
(PRDM16) (P < 0.01) was significantly decreased by arsenite treatment (Fig. 1C). Attenuated protein expression 
Figure 1. Arsenite exposure suppresses differentiation of HIB1B brown preadipocytes. (A) HIB1B brown 
preadipocytes were differentiated in the presence of increasing doses of arsenite (1–10 μM) or the vehicle 
control. (B) Oil Red O (ORO) staining was performed for cell morphology and ORO absorbance at Day 6 (D6) 
was measured. (C, D) After the differentiation of brown preadipocytes in the presence of increasing doses of 
Arsenite (1–10 μM) at Day 6, mRNA and protein expression of established brown markers were analyzed by 
qRT-PCR (C) and immunoblotting (D), respectively. At least 9 independent experiments were performed and 
all data was expressed as mean ± SEM. *P < 0.05 or **P < 0.01 by One-way ANOVA analysis.
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of UCP1, PGC1, and PPARγ (Fig. 1D) was consistent with decreased mRNA expression levels, suggesting that 
arsenite negatively affect differentiation of HIB1B brown preadipocytes by downregulating expression levels of 
essential brown adipocyte specific markers in both gene and protein.
Arsenite suppresses mitochondrial biogenesis and respiration in HIB1B brown adipocytes. 
Analysis of mRNA expression showed that arsenite also suppressed mRNA levels of nucleus-encoded mito-
chondrial genes, cytochrome c oxidase subunit IV a (Cox4a) and cytochrome b-c1 complex subunit 6 (Uqcrh), 
and transcription factors regulating mitochondrial gene expression, transcription factor A (Tfam) and nuclear 
respiratory factor 1 (Nrf-1) (Fig. 2A). Consistent with the mRNA expression results, mitochondrial biogenesis 
demonstrated by the staining of mitochondrial specific fluorescence MitoTracker Red was also decreased by 
arsenite treatment (Fig. 2B). To determine whether the suppression of mitochondria biogenesis by arsenite leads 
to decrease in mitochondrial uncoupling and thermogenesis, we examined oxygen consumption rates coupled 
with mitochondrial stress tests in brown adipocytes which have been differentiated in the presence or absence 
of arsenite by cellular bioenergetics measurements using XF24 Extracellular Flux Analyzers. Arsenite at 10 μM 
significantly decreased basal oxygen consumption rate (OCR) and proton leak; however, arsenite did not affect 
the maximal OCR, ATP production, and coupling efficiency (Fig. 2C,D).
Autophagy activity was inhibited by arsenite treatment during brown adipocyte differentia-
tion. We examined whether autophagy signaling underlies brown adipocyte differentiation, immunoblotting 
analysis showed that autophagy activity was up-regulated during brown adipocyte differentiation consistent with 
previous report in 3T3-L1 white adipocyte differentiation42. Autophagosome marker, microtubule-associated 
protein 1 light chain 3-II (LC3B-II, mammalian homologue of Atg8) and autophagosome substrate p62 (aka 
sequestosome 1) were both degraded by active autophagolysosome upto 50% by 10 µM arsenite treatment, phos-
phorylation of unc-51 like autophagy activating kinase 1 (ULK1) at Ser 555, which is AMPK target site, was 
increased and phosphorylation of ribosomal protein S6 kinase (S6K) at Thr 389, which is mTORC1 target site, was 
Figure 2. Arsenite dose-dependently suppresses mitochondria-associated marker genes, content and 
mitochondrial respiration in brown adipocytes. (A) Brown preadipocytes were differentiated in the presence 
of increasing doses of arsenite (1–10 μM) or the vehicle control. mRNA expression of mitochondrial structural 
genes, Cox4a, and Uqcrh, and transcriptional factors, Tfam and Nrf-1, at Day 6 (D6) was measured.  
(B) Mitochondrial content was analyzed by mitochondrial-specific fluorescence dye MitoTracker at Day 6. 
Relative fluorescence intensity was calculated from the mean fluorescence intensity values of the samples 
and expressed as fold of the control. (C) Brown preadipocytes were seeded in 24-well XF assay plates and 
differentiated in the presence of increasing doses of arsenite (1–10 μM) or the vehicle control until Day 6. 
The cells were subjected to real-time measurements of oxygen consumption rate. At least 9 independent 
experiments were performed and all data was expressed as mean ± SEM. *P < 0.05 or **P < 0.01 by One-way 
ANOVA analysis.
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decreased upon brown adipocyte differentiation process (Fig. 3A). We also confirmed that arsenite suppressed 
autophagy induction during brown adipocytes differentiation revealed by accumulation of both LC3B-II and p62 
upto 1.6 times in 10 μM of arsenite, decrease of ULK1 activity (p-Ser 555) and increase of S6K phosphorylation 
(p-Thr 389) when the cells were treated with arsenite in dose dependent manner (Fig. 3B). We examined the effect 
of the autophagy inhibitor, bafilomycine A1, on expression of brown adipocyte specific markers. Bafilomycine A1 
significantly attenuated the expression of UCP1, PGC1, and PPARγ protein expression levels in brown adipocytes 
(Fig. 3C), suggesting that autophagy pathway is necessary for brown adipogenesis, and supporting our hypothesis 
that arsenite suppresses brown adipocyte differentiation and function via autophagy inhibition through ULK1 
inhibition and mTORC1 activation (Fig. 3D).
Arsenite was heavily accumulated in brown adipose tissue of mice after oral administration. 
Knowing that arsenite treatment suppresses the differentiation and mitochondrial function of mouse brown 
adipocytes in dose dependent manner (Figs 1 and 2), we investigated whether arsenite can be accumulated 
on mouse BAT in physiological condition. First, the arsenic accumulation was quantified in mouse BAT and 
WAT using the inductively coupled plasma mass spectrometry (ICP-MS) after administration of arsenite by 
oral gavage at doses of 5 and 10 mg/kg once a day for 9 days (Fig. 4A,B). The control group was given water 
at the same volume of arsenite treatment groups. The relative amount of arsenite in BAT and WAT of those 
mice was compared. The concentration of arsenic accumulated in BAT was 4.5 times and 7.9 times higher than 










































Figure 3. Arsenite inhibits autophagy which is necessary during brown adipocytes differentiation. (A) HIB1B 
brown adipocytes were differentiated without arsenite treatment and whole cell lysates at Day 0, 2, 4, and 6 (D0, 
2, 4, and 6) were analyzed for autophagy activity. (B) Brown preadipocytes were differentiated in the presence 
of increasing doses of arsenite (1–10 μM) or the vehicle control until Day 6 (D6). Whole cell lysate was prepared 
and analyzed by immunoblotting with specific antibodies. (C) Arsenite (10 μM), Bafilomycin A1 (0.1 µM) 
or the vehicle control was treated during the differentiation of brown adipocytes and the protein levels of 
differentiation markers were measured by immunoblotting. (D) Schematic diagram depicting the toxic effect of 
arsenite on brown adipogenesis via inhibition of mitochondria function, thermogenesis and autophagy. At least 
9 independent experiments were performed.
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Although previous report identified that arsenic can majorly be accumulated in liver, kidney, and lung19,25, 
we never expected such a high and differential accumulation between BAT and WAT in mice. Given that the 
accumulated concentration of arsenic in BAT but not in WAT was increased in dose-dependent manner, we 
anticipated that some of physiological parameters of mouse would be affected by arsenite accumulation in BAT. 
However, we could not observe any significant differences in body weight (Fig. 4C) and food and water intakes 
(Fig. S2A) between control and arsenite treatment groups. We also did not observe any significant differences 
in oxygen consumption (VO2) and respiratory exchange ratio (RER, VO2/VCO2) when normalized by mouse 
body weight (Fig. S2B,C).
Arsenite down regulates the gene expression of brown adipose markers in vivo. To evaluate 
the effects of accumulated arsenite on BAT homeostasis in mice, we measured mRNA expression of brown 
adipose specific markers, UCP1, PGC1, PPARγ, and PRDM16, after the oral administration of arsenite at 
doses of 5 and 10 mg/kg/day for 9 days (Fig. 5A). Lipogenic gene, PGC1 and PPARγ, expression levels of 
10 mg/kg group were significantly down regulated compared to those of control group (P < 0.05). The mRNA 
expression of nucleus-encoded mitochondrial biogenesis genes, Cox4a, Uqcrh, Tfam, and Nrf-1, were also 
measured on mice BAT (Fig. 5B). Uqcrh and Nrf-1 gene expression levels of 10 mg/kg group were significantly 
decreased compared to those of control group (P < 0.01). These data suggest that arsenite accumulated in 
10 mg/kg group effectively suppresses brown adipocyte function and mitochondrial biogenesis. A well-known 
function of BAT is non-shivering thermogenesis that has been spotlighted in the regulation of obesity pan-
demic43,44. Since UCP1 expression is augmented when exposed to cold in BAT of mice45, we hypothesized 
that UCP1 inhibition by arsenite would be more dramatic and significant because UCP1 is further induced 
under by cold exposure. To investigate the effects of arsenite on UCP1 expression in non-shivering thermo-
genesis in mouse BAT, we challenged the mice in cold condition (4 °C) for 24 hrs at the last day of arsen-
ite administration (Fig. 4A). Arsenite administration (10 mg/kg) significantly reduced UCP1 (P < 0.01) and 
PPARγ (P < 0.05) gene expression levels while there was no significant difference in PGC1 and PRDM16 gene 
expression levels (Fig. 5A). In the case of genes involved in mitochondrial biogenesis, Tfam and Nrf-1 gene 
expression levels of 10 mg/kg group were significantly reduced compared to those of control group (P < 0.05) 
whereas Cox4a and Uqcrh had no significant difference (Fig. 5B). Consistent with the gene expression level 
of UCP1, protein expression level of UCP1 was also suppressed by arsenite exposure in cold condition in 
mice BAT (Fig. 5C). Combined together, these data suggest that arsenite (10 mg/kg for 9 days) may suppress 
Figure 4. Arsenite is heavily accumulated in brown adipose tissue (BAT) but not in white adipose tissue 
(WAT) of mice. (A) Experimental design for mouse work. (B) The arsenic accumulation was quantified in 
eWAT, ingWAT, and BAT of C57BL/6 mouse using ICP-MS after the oral administration of arsenite at doses of 
0 (control), 5, and 10 mg/kg/day for 9 days (n = 6). Adipose tissues of all mice were collected on Day 10 under 
anesthesia with isoflurane and CO2. (C) Measurement of body weights (n = 12). All data was expressed as 
mean ± SEM. *P < 0.05 or **P < 0.01 by One-way ANOVA analysis.
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thermogenesis through the inhibition of UCP1 expression. Consistent with the suppression of adipogenesis 
genes such as PGC1 and PPARγ, arsenite decreased the lipid droplet (LD) diameter of BAT in mice at room 
temperature (23 °C). However, in the BAT of mice exposed to cold (4 °C) for 24 hrs at the last day of arsenite 
administration, LD diameter was not significantly changed regardless of arsenite doses (Fig. 5D) possibly due 
to no significant change in PGC1 and PRDM16. Nevertheless, the overall reduction of lipid content under cold 
temperature relative to room temperature would reflect the induction in thermogenesis by activating UCP1 in 
Figure 5. Arsenite down regulates the gene expression of brown adipocyte markers including thermogenesis 
gene UCP1 of mouse BAT in vivo. (A,B) mRNA expression levels of BAT markers (A) and mitochondrial 
biogenesis genes (B) were analyzed by qRT-PCR after the oral administration of arsenite into mice at doses 
of 0 (control), 5, and 10 mg/kg/day for 9 days. Mice were challenged with room temp (RT, 23 °C) control or 
cold temp (Cold, 4 °C) for 24 hrs on the last day of oral gavage to evaluate thermogenesis function (n = 6). 
(C) Protein expression level of UCP1 from mice BAT after administered with 0 (control), 5, and 10 mg/
kg/day arsenite for 9 days (RT) and exposed to cold temp for 24 hrs before euthanization was analyzed by 
immunoblotting (n = 3). Relative band intensities were quantified through densitometry (ImageJ, NIH). (D) 
H&E staining of mouse BAT after arsenite administration and quantitative analysis of lipid droplet size (n = 6). 
Black scale bars represent 100 μm. (E) TEM image of mouse BAT after arsenite administration and quantitative 
analysis of relative number of intact and damaged mitochondria (n = 3). LD, lipid droplet, M, mitochondria. 
Scale bar, 800 nm. All data was expressed as mean ± SEM. *P < 0.05 or **P < 0.01 by One-way ANOVA 
analysis.
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BAT. The UCP1 inhibition by arsenite could not be enough to observe a significant increase in LD diameter. 
Transmission electron microscopy (TEM) image reveals that there was 3 and 4 fold increase in the number of 
either sick (e.g. missing cristae structure) or broken (e.g. ruptured outer membrane structure) mitochondria 
in BAT collected from mice in 5 and 10 mg/kg arsenite-administered groups, respectively (Fig. 5E). Total BAT 
mass was significantly reduced in the group of 10 mg/kg arsenite administration (Fig. S3) due to the decrease 
in adipogenesis and LD droplet size and mitochondrial biogenesis.
Arsenite blocks autophagy activity through Sestrin2 and ULK1 inhibition in vivo. It was 
reported that short term treatment or exposure of arsenite increases reactive oxygen species (ROS) level and 
induces autophagy as a defense mechanism in human uro-epithelial cells46. To investigate the effect of arsen-
ite treatment on autophagy activity in BAT, we measured mRNA expression of essential autophagy genes (e.g., 
ULK1, Atg5, Atg7, and LC3B), stress-inducible protein Sestrin2, and autophagy receptor p62 under our experi-
mental conditions. Sestrin2, ULK1, and p62 were significantly downregulated by arsenite (10 mg/kg BW of mice) 
(Fig. 6A) suggesting that arsenite may inhibit autophagy by downregulating genes involved in ULK1 induction as 
well as p62 receptor association with autophagosome. Sestrin2 inhibits mTORC1 through AMPK activation47,48. 
Therefore, arsenite may inhibit gene expression of Sestrin2 to lead to mTORC1 activation through AMPK inhibi-
tion and subsequent autophagy inhibition. Although our immunoblotting data displayed a significance decrease 
in Sestrin2 and ULK1 expression levels in response to arsenite administration (10 mg/kg), there was no signif-
icant difference in both phosphorylation of S6K (a mTORC1 target) at Thr 389 and phosphorylation of ACC 
(an AMPK target) at Ser 79 (Fig. 6B). These data collectively suggest that the autophagy inhibition by arsenite is 
mainly attributed to the inhibition of Sestrin2 and ULK1 expression but not through direct mTORC1 or AMPK 
regulation. While arsenite may directly inhibit autophagosome maturation by inhibiting p62, there was no signif-
icant effect of arsenite on the expression of genes involved in the Atg5-, Atg7-, or LC3B- dependent autophago-
some conjugation system (Fig. 6C).
Figure 6. Arsenite inhibits autophagy in mouse BAT. (A) mRNA expression levels of autophagy genes in mouse 
BAT were analyzed after the oral administration of arsenite into mice at doses of 0 (control), 5, and 10 mg/kg/
day for 9 days. (B) Protein expression levels of autophagy pathway genes were measured by immunoblotting 
in mouse BAT (n = 3) after arsenite administration. Relative phosphorylation band intensities were quantified 
through densitometry (ImageJ, NIH) and presented as mean ± SEM (n = 3). *P < 0.05 by One-way ANOVA 
analysis. (C) Proposed model of how arsenite suppresses autophagy activity in BAT. Arsenite administration 
suppresses autophagy mainly through direct inhibition of Sestrin2 and ULK1. Arsenite suppresses gene 
expressions of p62 so that autophagosome receptor binding is blocked in mouse BAT. Arsenite has no 
significant effect on Atg5- or Atg7-dependent autophagosome conjugation system.
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Discussion
Increased consumption of high carbohydrate and fat containing food and westernized diet would have been a 
serious concern correlated with the increased rate of morbidity due to metabolic diseases such as obesity, diabe-
tes, cardiovascular diseases, and cancer. Particularly combined with the exposure to harmful environmental pol-
lutants and genotoxic agents in the food, water and air, it would have been major attention in combating against 
metabolic diseases in the modern society19,49. United States environmental protection agency (EPA) classified 
arsenic as a Group 1A carcinogen. Over decades, majority of studies have focused on arsenic carcinogenesis in 
skin, lung, liver, and urinary bladder and the increased level of oxidative stress, mitochondria DNA damage, 
mitochondrial biogenesis, and mutation in arsenic sensitive oncogenes were believed to be major contributing 
factors in human50. Unlike arsenic carcinogenesis studies, the studies on the effect of arsenic on the adipose tissue 
metabolism, mitochondrial function in obesity were very limited albeit the positive correlation between arsenite 
exposure and diabetes mellitus in Michigan residing human studies25, and population studies in high arsenic 
areas (≥150 µg/L drinking water) of Taiwan and Bangladesh51, and the molecular mechanism underlying the 
arsenic-induced metabolic disorders is still remained unclear.
Other arsenic research groups reported that acute high dose of arsenic (>500 nM) increases ROS and sub-
sequently upregulates antioxidant genes such as heme oxygenase and Nrf2 to protect cells from mitochondria 
damage and oxidative DNA damage52. However, low dose of arsenic (<500 nM) upto 24 hrs treatment decreases 
ROS by inducing antioxidant genes53. Furthermore, low dose of arsenic promotes cell proliferation by increasing 
mitochondrial biogenesis in skin cancer cells54. It is still debatable but generally ROS-mediated cell damage and 
apoptosis would be considered as mechanism underlying arsenic-induced toxicity. Our data suggest that upto 10 
μM of arsenite treatment did not affect the cell survival without apoptosis induction, so we investigated the effect 
of arsenite treatment during the course of brown adipocyte differentiation. Arsenite treatment suppressed differ-
entiation and inhibited mitochondrial biogenesis of brown adipocytes in a dose dependent manner. This data was 
consistent with the inhibition of white adipocyte differentiation in previous studies29,30. However, we observed 
7.9 times more accumulation BAT compared to eWAT in 10 mg/kg administration of arsenite in mice. This data 
would suggest that arsenite-associated obesity is not only affected by inhibition of WAT function and is further 
aggravated by the malfunction of BAT in vivo. It needs further investigation why the arsenic is much heavily 
accumulated in BAT among adipose tissues in mice. It is possible that arsenic directly bind to the promoters of 
genes involved in the mitochondrial biogenesis or blocking mitochondrial turnover through inhibiting autophagy 
gene expression or autophagy protein activity by direct binding. Our group and others would investigate the indi-
vidual arsenic specific target genes and its inhibition mechanism as further studies. High level of accumulation 
of arsenic prevent normal cell differentiation of adipose tissues and cause the imbalance in fat metabolism and 
mitochondrial functions, which can contribute to the development of metabolic disorders such as obesity and 
diabetes. ACC gene expression essential for lipid biogenesis was also suppressed in arsenite-administered mice 
group. Consistently, we have observed decrease in the lipid droplet content in BAT upon arsenite administration. 
Another notable result is that arsenite treatment suppresses UCP1 gene expression in the mitochondria, which 
are essential for thermogenic function of brown fat to dissipate energy as a heat55. In live mice, we observed 
similar result while total food and water intake, oxygen consumption and RER were not changed. It is possible 
that there would be compensation mechanism from other tissues protecting mice since oxygen consumption 
and RER are vital signs essential for survival. Transgenic overexpression of mitochondrial uncoupling protein 
UCP1-3 in skin of mice showed strong resistance to chemically induced carcinogenesis, suggesting that inhibition 
of mitochondrial respiration through enhancing mitochondrial uncoupling would be a therapeutic target against 
arsenic-induced cancer56. In the same context, UCP1 overexpression or UCP1 enhancing drugs would be a poten-
tial treatment to protect adipose tissues from arsenic-induced metabolic disorders. It is plausible that proper dose 
of arsenic chelating agents such as BAL, DMPS, and DMSA57 or overexpressing arsenic-sequestrating proteins 
such as Hexokinase-2 (HK2)58 in BAT would be beneficial in improving lipid metabolism, mitochondrial func-
tion and thermogenesis, which contribute on the prevention or treatment of arsenic-induced metabolic disorders.
Short term treatment upto 48 hrs or acute exposure of arsenite induces autophagy evidenced by increasing lipi-
dated form of LC3B (LC3B-II) and decreasing level of p62 autophagy receptor in cardiac cells, neuronal cells, and 
cancer cells59–61. Arsenite-induced ROS in short term treatment have been suggested as a main cause to induced 
autophagy activity62. However, in recent studies using NIH3T3 fibroblasts, 4 hrs of short term treatment of arsen-
ite activates Nrf2 pathway through autophagy inhibition63. Indeed, in our autophagy studies using HIB1B brown 
adipocytes, we observed increased level of LC3B-II accumulation along with the accumulation of p62 by arsenite, 
which support the inhibition of autophagy pathway. Treatment of autophagy blocker, bafilomycin A1 also com-
pletely suppress the genes of brown adipogenesis, which also support the inhibition of brown adipocyte differentia-
tion via autophagy inhibition by arsenite. It has been reported by several independent groups that a loss of essential 
autophagy genes such as Atg5 and Atg7 leads to the formation of p62-positive aggregates and accumulation of 
ubiquitinated protein inclusion body and Mallory bodies in the liver64–66. Autophagy has two LC3B or Atg8 conjuga-
tions systems, Atg5-Atg1267 and Atg4-Atg7-Atg368,69. However, our data showed that arsenite mediated autophagy 
inhibition in BAT is independent of Atg5 and Atg7 (P < 0.06). Rather, Sestrin2, ULK1 and p62 inhibition by arsenite 
accumulation is the underlying mechanism of autophagy inhibition in BAT. Recently, Gao et al. reported that arsen-
ite treatment upto 10 μM for short term 24 hrs blocks autophagy flux through LncRNA UCA1 mediated activation 
of mTORC1/S6K pathway in human hepatocytes70. However, in our studies, arsenite treatment through oral gavage 
over longer term 9 days in mice suppressed Sestrin2 and ULK1 gene expressions but not significantly inhibiting 
AMPK and activating mTORC1. Ro et al. previously reported that Sestrin2 can directly bind with ULK1 and activate 
autophagy induction possibly independently from mTORC1 and AMPK71. Longer arsenite exposure would directly 
regulates gene expression levels of Sestrin2 and ULK1 to inhibit autophagy. Differently from cell culture model, there 
might be a compensation mechanism that maintains mTORC1 or AMPK activity under arsenite-induced toxicity 
in mammals. Our TEM image data also suggested that inhibition of autophagy activity in arsenite treatment groups 
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may contribute on the accumulation of damaged mitochondria in BAT. Autophagy inhibition by arsenite exposure 
would lead to irreversible apoptotic cell death which we observed in the reduction of total BAT mass including both 
mitochondria and lipid mass by arsenite. In this regard, autophagy enhancing drugs such as metformin, torins and 
resveratrol72 or the overexpression of autophagy induction proteins such as Sestrin2 and ULK1 would be protective 
mechanism against deregulation or loss of BAT functions affected by arsenic-induced toxicity. While our group 
is preparing the manuscript, two recent papers came out on publication. Consistent with our data suggesting the 
autophagy inhibition by arsenite, Dodson et al. from Dr. Zhang’s group treated As (III) concentrations ranging 0.5 to 
5 µM [37.5 to 375 ppb] in NIH 3T3 fibroblasts upto 48 hrs and observed that arsenic inhibits SNARE complex forma-
tion by enhancing O-GlcNAcylation of SNAP29 and drives autophagy dysfunction73. However, in another arsenic 
research group suggested that arsenic at 50 ppm (equivalent of 50,000 ppb or 667 µM) in drinking water administra-
tion in NMRI mice under 20 weeks of HFD actually increased both macroautophagy and Chaperon-mediated auto-
phagy (CMA) in liver tissues74. Since the macroautophagy response is more rapid and the CMA is activated when 
macroautophagy is inhibited or defective under prolonged nutritional stress75–77, the upregulation of gene expression 
levels of both macroautophagy and CMA genes would be a compensation effect of serious macroautophagy or CMA 
defect and possible non-apoptotic cell death in liver. From these recent publications, we speculate that the arsenic 
effect on autophagy function is highly debatable depending on arsenic concentrations, time, tissue types, and mice 
species. Therefore, our study has proposed a unique mechanism and is an independent research from liver studies 
regarding the long term arsenic effect on BAT function and autophagy.
In conclusion, we propose a model where arsenite exposure consistently suppresses the brown adipocyte dif-
ferentiation, mitochondrial biogenesis and function, thermogenesis, and autophagy function, which would have 
harmful effect on metabolic balance in human body and leads to metabolic disorders. Our study supports the previ-
ous human studies performed in US and other developing countries in the world that have higher concentration of 
arsenite contamination in water and soil would develop higher chances of development of metabolic disorders such 
as obesity and diabetes23–25. We believe that our study provides new clues on the connections between arsenite expo-
sure and metabolic disorders by highlighting the major metabolic functions of BAT, which seemingly has higher 
accumulation of arsenic in our body. Balancing the BAT differentiation, mitochondrial integrity, thermogenesis, and 
autophagy activity would be novel protective mechanisms against arsenic-induced toxicity and metabolic disorders.
Methods
Reagents and antibodies. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Invitrogen 
(San Diego, CA). Fetal bovine serum (FBS), 3-isobutyl-L-methylxanthine, T3, dexamethasone, insulin, indo-
methacin, and Oil Red O were purchased from Sigma-Aldrich (St. Louis, MO). MTT cell growth assay kit was 
purchased from Sigma-Aldrich (St. Louis, MO). Primary antibodies against PPARγ, phospho-AMPK (T172), 
phospho-ULK1 (Ser555), ULK1, phospho-ACC (Ser79), ACC, and S6K were purchased from Cell Signaling 
Technology (Danvers, MA). Tubulin and Actin antibodies was purchased from Developmental Studies 
Hybridoma Bank (Iowa City, IA). PGC1α, phospho-S6K (Thr389), and AMPK antibodies were purchased from 
Santa Cruz Biotechnology (Dallas, TX) and UCP1 antibody was purchased from Alpha Diagnostic (San Antonio, 
TX). Sodium arsenite (NaAsO2) was obtained from Sigma-Aldrich (St. Louis, MO) and a stock solution was pre-
pared at a final concentration of 100 mM and was diluted for a working concentration in water (ddH2O).
Brown preadipocyte culture and adipocyte differentiation. Immortalized HIB1B murine brown 
preadipocyte cell line, generated from the interscapular brown fat of C57BL/6 mice, is a gift from Dr. Johannes 
Klein (University of Lubeck, Lubeck, Germany)78. Brown preadipocytes were maintained in DMEM supple-
mented with 20% FBS at 37 °C humidified atmosphere of 5% CO2 in air. The differentiation of brown preadipo-
cytes was as previously described79. Briefly, cells were plated and grown in DMEM supplemented with 20% FBS 
until confluency (designed as D0). The cells were then changed into DMEM supplemented with 20% FBS, 1 nM 
T3, 20 nM insulin, 0.125 mM indomethacin, 5 μM dexamethasone, and 0.5 mM 3-isobutyl-L-methylxanthine for 
24 hrs, followed by DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM insulin, replenished every two days 
until the cells were fully differentiated at Day 6 (D6). Sodium arsenite was added to the media at D0 and replaced 
with each change of the media during the process. All experiments were performed in room temperature (23 °C) 
unless it is specifically indicated as in cold temperature (4 °C).
Oil red O staining and quantification. Fully differentiated brown adipocytes were fixed with 10% for-
malin overnight, and the lipid droplets were stained with Oil Red O and quantified by absorbance at 500 nm in a 
spectrophotometer.
immunoblotting analysis. Total cell lysates were prepared in RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 
1% sodium deoxycholate, 1% NP-40; 0.1% SDS) or cell lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1% Triton-X-100) containing 
protease inhibitor cocktail (Roche) and phosphatase inhibitor (Sigma) and protein concentrations were determined 
by BCA assay kit (Thermo Scientific, Waltham, MA). Thirty micrograms of total cell lysates were subjected to 4–20% 
SDS-PAGE and transferred to polyvinylidene difluoride membrane. The membrane was blocked in 20 mM Tris-HCl, 
137 mM NaCl, and 0.2% Tween 20 (pH 7.6) containing 5% nonfat milk. The membrane was immunoblotted with pri-
mary antibodies at 4 °C overnight followed by secondary antibody conjugated with horseradish peroxidase (Bio-Rad, 
Hercules, CA) for 1 hr. The membrane was exposed on X-ray film using ECL Western blot detection reagents (Pierce 
Biotechnology, Rockford, IL) or digitally captured using Odyssey blot imager (LI-COR, Lincoln, NE). Raw uncropped 
images with molecular size marker were displayed in the supplementary section (Figs S4–S9). Immunoblot band den-
sity was measured by ImageJ program (National Institute of Health) and normalized by the intensity of loading control 
(Tubulin or Actin) as indicated.
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RnA preparation and quantitative real-time pcR analysis. Total RNA was prepared using 
TRIzol (Invitrogen). Total RNA abundance was quantified using a NanoDrop Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). Reverse transcription was carried out using High Capacity cDNA Reverse 
Transcription kit (Thermo Scientific, Pittsburgh, PA) according to the manufacturer’s instructions. mRNA 
expression of target genes and housekeeping gene (Table S1) were measured quantitatively using SsoAdvanced 
Universal SYBR Green Supermix (Bio-Rad, Hercules, CA). PCR reactions were run in 96-well plate using MyiQ 
Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Cycle conditions were 95 °C for 5 min, then 40 cycles 
of 95 °C for 15 sec/60 °C for 30 sec. Relative gene expression was calculated using the 2−ΔΔCt method, which nor-
malizes against loading control β-actin.
Analysis of mitochondrial content by Mitotracker staining. Mitochondria were labeled using the 
mitochondria-specific dye MitoTracker Red (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. 
Briefly, the differentiated brown adipocytes were washed and incubated with 100 nM MitoTracker Red for 30 min at 
37 °C. Image was taken with Leica DMI4000B fluorescence microscope (Leica Microsystems, Wetzlar, Germany). 
The fluorescence intensity was measured with Synergy H1 Hybrid Multi-Mode Reader (BioTek Instruments, 
Winoosk, VT). Relative fluorescence intensity is the fold of the mean fluorescence intensity of the controls.
Mitochondrial respiration measurements. Five thousand of brown preadipocytes were seeded in 
gelatin-coated 24-well XF assay plates in the 10% FBS containing DMEM and differentiated in the presence 
or absence of arsenite for 6 days. Differentiated brown adipocytes were rinsed 3 times, changed to 500 µL of 
XF assay buffer, and equilibrated at non-CO2 incubator at 37 °C for 1 hr. The cells subjected to real-time meas-
urements of oxygen consumption rate (OCR) using XF24 Extracellular Flux Analyzer (Agilent Seahorse, Santa 
Clara, CA) as previously reported45,55. For mitochondrial stress tests, mitochondrial complex inhibitors were 
injected to all of the following treatments sequentially in the following order: oligomycine (1 µM), carbonyl 
cyanide-ptrifluoromethoxyphenylhydrazone (FCCP; 0.75 µM), antimycine A/rotenone (2.5 µM each), and 3 
readings were taken after each injection. OCR was automatically recorded by XF24 software v2.3 provided by the 
manufacturer. Calculations of proton leak, coupling efficiency, maximal respiration, and ATP production were 
performed according to the manufacturer’s instructions.
Animal handling. Housing and use of mice in the study were performed in compliance with the National 
Institute of Health (NIH) Principles for the Use of Animals, the American Veterinary Medical Association 
(AVMA) Guidelines, and the Public Health Service Policy on Humane Care and Use of Laboratory Animals 
awarded by University of Nebraska-Lincoln (Animal Welfare Assurance Number: A3459-01). Animal care and 
experimental procedures were approved by the institutional Animal Care and Use Committee (IACUC Approval 
Number: 1310 and 1527). Seven-week-old male C57BL/6J mice (Stock No. 000664, 21–23 g) were purchased from 
Jackson Laboratory (Bar Harbor, ME)80–82. They were maintained for a week to acclimate to their new environ-
ment before performing the experiments. Animals were housed in a group of three or four mice per cage (501 cm2 
floor area; Tecniplast, Italy) with Tek-Fresh bedding (Harlan Teklad, Madison, WI) under a 12-h light/dark cycle 
from 06:00 to 18:00. They were fed the standard chow diet (Catalog #2016C, Envigo, Madison, WI) contains16% 
protein and 4% fat to cover 12% of total kcal and sterilized drinking water ad libitum. Mice were euthanized 
according to IACUC protocol after the completion of experiments.
oral administration of arsenite in mice and tissue collection. Sodium arsenite stock solution at 200 mg/
mL was prepared by dissolving in distilled regular water. The arsenite stock solution was aliquoted and stored in 
−80 °C until use. The arsenite was orally administered to mice at doses of 5 and 10 mg/kg after diluting the arsenite 
stock solution with distilled water (n = 6 per group). A control group was given regular water at a dosing volume of 
5 mL/kg which was comparable to the volume of arsenite administered groups83,84. The arsenite was administered 
to mice once a day for 9 days (Day 1 to 9)85–88. In the case of in vivo, we wanted to quantify the accumulated amount 
of arsenic in mice adipose tissues. The major source of arsenic exposure is drinking water and food. The exposure 
ordinarily occurs chronically. To ensure all mice ingested equal arsenic, we decided to administer arsenite to mice 
orally by gavage rather than including it in drinking water and food. The arsenic dose and treatment period were 
determined by tissue distribution and toxicity in consideration of the previous reports83–88. To check the levels of 
mRNA in BAT and to compare the change of them under different temperature, mice were divided into room tem-
perature (RT, 23 °C) or cold temperature (4 °C). The mice under cold condition were transferred to cold room (4 °C) 
on Day 9 for 24 hrs. The body weight of mice was measured from Day 0 to 10. The epididymal white adipose tissue 
(eWAT), inguinal white adipose tissue (ingWAT), and interscapular brown adipose tissue (BAT) of all mice were 
collected on Day 10 under anesthesia with isoflurane and CO2. All samples were measured individually and stored 
at −80 °C until use. All experiments were performed in RT unless it is specifically indicated as in cold temperature.
Quantification of arsenic content in adipose tissue. Arsenic analysis was performed using an Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS) 7500cx series (Agilent Technologies, Santa Clara, CA) and an ESI SC-4 
high-throughput auto sampler (Elemental Scientific, Omaha, NE). All mice adipose tissue (eWAT, ingWAT or BAT) 
samples were homogenized in PBS containing Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland). To 
normalize the lysate samples, the amount of protein in each lysate was measured using the Bradford Protein Assay 
(Bio-Rad, Hercules, CA). The adipose tissue samples were suspended in 200 µL of nitric acid with 50 µg/L of gallium 
as an internal standard. For complete digestion of fat, WAT samples were incubated overnight with 200 µL of nitric 
acid and internal standard followed by adding 200 µL of H2O2 and incubated for 15 hrs. The suspended adipose tissue 
samples were diluted 1–20 times into the auto sampler plate to analysis the arsenic content. Each sample was analyzed 3 
times. The carrier solution was 1.5% nitric acid at a flow rate of 70 mL/min and the injection volume was 70 μL.
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transmission electron microscopy (teM) imaging. Brown adipocyte tissue was extracted from mice 
and reduced to three 1-mm pieces. Samples were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer 
(pH 7.4) for 1 hr at RT and then overnight at 4 °C. Samples were then post-fixed with 1% osmium tetroxide for 
1 hr at RT. Fixed tissues were dehydrated through a graduated ethanol series and embedded In Spurr (Electron 
Microscopic Sciences, Fort Washington, PA). Ultrathin sections (~80 nm) were stained with uranyl acetate and 
lead citrate and observed under a transmission electron microscope (Hitachi H7500-I). A series of ultrastructural 
images were collected with a bottom-mount digital camera.
Measurement of food and water intake and mitochondrial respiratory rate. The food and water 
intakes and respiratory rate of mice were measured using metabolic cages (TSE systems, Chesterfield, MO) dur-
ing arsenite treatment period (n = 4 per group). The metabolic profiles were investigated by a computer con-
trolled monitoring systems of metabolic cages as previously reported45. Mice were housed in groups before they 
were in the metabolic cages (Day 0 to 2) and then acclimated in metabolic cages, one mouse per cage, for a day 
(Day 3). They also were in the metabolic cages alone while the food and water intakes and respiratory rate were 
measured for 5 days (Day 4 to 9).
Histology. A portion of the collected BAT samples was prepared for histology. Theses tissues were placed 
in cassettes and fixed in 10% formalin. All tissues were processed on a Leica Peloris tissue processor (Leica 
Biosystems, Wetzlar, Germany). The prepared sections (4 microns) were stained with haematoxylin and eosin 
(StatLab, McKinney, TX). Tissue slides were evaluated by light microscopy at 400X magnification. Six micropho-
tographs per mouse were obtained. The lipid-droplet diameter of BAT tissues was calculated from the mean of 
ten values per microphotograph.
Statistical analysis. All data are presented as mean ± SEM. Measurements were performed at least in trip-
licates. Statistical analysis was performed using SPSS 25 (IBM Coperation, Armonk, NY). One-way ANOVA was 
performed by Tukey’s multiple comparison test to determine the differences of group mean among control and 
two treatment groups. The level of significance was set at *P < 0.05 or **P < 0.01.
References
 1. Shigetoh, Y. et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general 
population. Am J Hypertens 22, 151–155, https://doi.org/10.1038/ajh.2008.331 (2009).
 2. Re, R. N. Obesity-related hypertension. Ochsner J 9, 133–136 (2009).
 3. Apovian, C. M. & Gokce, N. Obesity and cardiovascular disease. Circulation 125, 1178–1182, https://doi.org/10.1161/
CIRCULATIONAHA.111.022541 (2012).
 4. Basen-Engquist, K. & Chang, M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 13, 71–76, https://doi.
org/10.1007/s11912-010-0139-7 (2011).
 5. Lee, Y. H., Mottillo, E. P. & Granneman, J. G. Adipose tissue plasticity from WAT to BAT and in between. Biochim Biophys Acta 1842, 
358–369, https://doi.org/10.1016/j.bbadis.2013.05.011 (2014).
 6. McMillan, A. C. & White, M. D. Induction of thermogenesis in brown and beige adipose tissues: molecular markers, mild cold exposure 
and novel therapies. Curr Opin Endocrinol Diabetes Obes 22, 347–352, https://doi.org/10.1097/MED.0000000000000191 (2015).
 7. Saely, C. H., Geiger, K. & Drexel, H. Brown versus white adipose tissue: a mini-review. Gerontology 58, 15–23, https://doi.
org/10.1159/000321319 (2012).
 8. van Marken Lichtenbelt, W. D. & Schrauwen, P. Implications of nonshivering thermogenesis for energy balance regulation in 
humans. Am J Physiol Regul Integr Comp Physiol 301, R285–296, https://doi.org/10.1152/ajpregu.00652.2010 (2011).
 9. Virtanen, K. A., van Marken Lichtenbelt, W. D. & Nuutila, P. Brown adipose tissue functions in humans. Biochim Biophys Acta 1831, 
1004–1008, https://doi.org/10.1016/j.bbalip.2012.12.011 (2013).
 10. Azzu, V. & Brand, M. D. The on-off switches of the mitochondrial uncoupling proteins. Trends Biochem Sci 35, 298–307, https://doi.
org/10.1016/j.tibs.2009.11.001 (2010).
 11. Brondani, L. A. et al. The role of the uncoupling protein 1 (UCP1) on the development of obesity and type 2 diabetes mellitus. Arq 
Bras Endocrinol Metabol 56, 215–225 (2012).
 12. Cohen, P. et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 
156, 304–316, https://doi.org/10.1016/j.cell.2013.12.021 (2014).
 13. Harms, M. & Seale, P. Brown and beige fat: development, function and therapeutic potential. Nat Med 19, 1252–1263, https://doi.
org/10.1038/nm.3361 (2013).
 14. Lanthier, N. & Leclercq, I. A. Adipose tissues as endocrine target organs. Best Pract Res Clin Gastroenterol 28, 545–558, https://doi.
org/10.1016/j.bpg.2014.07.002 (2014).
 15. Cypess, A. M. et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360, 1509–1517, https://
doi.org/10.1056/NEJMoa0810780 (2009).
 16. van Marken Lichtenbelt, W. D. et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 360, 1500–1508, https://doi.
org/10.1056/NEJMoa0808718 (2009).
 17. Holstila, M. et al. Measurement of brown adipose tissue mass using a novel dual-echo magnetic resonance imaging approach: a 
validation study. Metabolism 62, 1189–1198, https://doi.org/10.1016/j.metabol.2013.03.002 (2013).
 18. Park, J. W. et al. 18F-FDG PET/CT monitoring of beta3 agonist-stimulated brown adipocyte recruitment in white adipose tissue. J 
Nucl Med 56, 153–158, https://doi.org/10.2967/jnumed.114.147603 (2015).
 19. Hughes, M. F., Beck, B. D., Chen, Y., Lewis, A. S. & Thomas, D. J. Arsenic exposure and toxicology: a historical perspective. Toxicol 
Sci 123, 305–332, https://doi.org/10.1093/toxsci/kfr184 (2011).
 20. Kleiman, N. J., Quinn, A. M., Fields, K. G., Slavkovich, V. & Graziano, J. H. Arsenite accumulation in the mouse eye. J Toxicol 
Environ Health A 79, 339–341, https://doi.org/10.1080/15287394.2016.1151392 (2016).
 21. Li, Q. et al. The preferential accumulation of heavy metals in different tissues following frequent respiratory exposure to PM 2.5 in 
rats. Sci Rep 5, 16936, https://doi.org/10.1038/srep16936 (2015).
 22. Perry, M. R., Wyllie, S., Raab, A., Feldmann, J. & Fairlamb, A. H. Chronic exposure to arsenic in drinking water can lead to resistance 
to antimonial drugs in a mouse model of visceral leishmaniasis. Proc Natl Acad Sci USA 110, 19932–19937, https://doi.org/10.1073/
pnas.1311535110 (2013).
 23. D’Ippoliti, D. et al. Arsenic in Drinking Water and Mortality for Cancer and Chronic Diseases in Central Italy, 1990–2010. PLoS One 
10, e0138182, https://doi.org/10.1371/journal.pone.0138182 (2015).
 24. Brauner, E. V. et al. Long-term exposure to low-level arsenic in drinking water and diabetes incidence: a prospective study of the 
diet, cancer and health cohort. Environ Health Perspect 122, 1059–1065, https://doi.org/10.1289/ehp.1408198 (2014).
1 2Scientific RepoRtS |         (2019) 9:14464  | https://doi.org/10.1038/s41598-019-50965-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Meliker, J. R., Wahl, R. L., Cameron, L. L. & Nriagu, J. O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, 
and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health 6, 4, https://doi.org/10.1186/1476-069X-6-4 
(2007).
 26. Renu, K. et al. Role of arsenic exposure in adipose tissue dysfunction and its possible implication in diabetes pathophysiology. 
Toxicol Lett 284, 86–95, https://doi.org/10.1016/j.toxlet.2017.11.032 (2018).
 27. Ceja-Galicia, Z. A. et al. Effects of arsenic on adipocyte metabolism: Is arsenic an obesogen? Mol Cell Endocrinol 452, 25–32, https://
doi.org/10.1016/j.mce.2017.05.008 (2017).
 28. Klei, L. R., Garciafigueroa, D. Y. & Barchowsky, A. Arsenic activates endothelin-1 Gi protein-coupled receptor signaling to inhibit 
stem cell differentiation in adipogenesis. Toxicol Sci 131, 512–520, https://doi.org/10.1093/toxsci/kfs323 (2013).
 29. Wang, Z. X. et al. The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res 15, 379–386, 
https://doi.org/10.1038/sj.cr.7290305 (2005).
 30. Trouba, K. J., Wauson, E. M. & Vorce, R. L. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. 
Toxicol Appl Pharmacol 168, 25–35, https://doi.org/10.1006/taap.2000.9012 (2000).
 31. Garciafigueroa, D. Y., Klei, L. R., Ambrosio, F. & Barchowsky, A. Arsenic-stimulated lipolysis and adipose remodeling is mediated 
by G-protein-coupled receptors. Toxicol Sci 134, 335–344, https://doi.org/10.1093/toxsci/kft108 (2013).
 32. Galluzzi, L. et al. Molecular definitions of autophagy and related processes. EMBO J 36, 1811–1836, https://doi.org/10.15252/
embj.201796697 (2017).
 33. Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. 
Science 331, 456–461, https://doi.org/10.1126/science.1196371 (2011).
 34. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell 
Biol 13, 132–141, https://doi.org/10.1038/ncb2152 (2011).
 35. Jung, C. H. et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 20, 1992–2003, 
https://doi.org/10.1091/mbc.E08-12-1249 (2009).
 36. Jung, C. H., Ro, S. H., Cao, J., Otto, N. M. & Kim, D. H. mTOR regulation of autophagy. FEBS Lett 584, 1287–1295, https://doi.
org/10.1016/j.febslet.2010.01.017 (2010).
 37. Katsuragi, Y., Ichimura, Y. & Komatsu, M. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J 282, 
4672–4678, https://doi.org/10.1111/febs.13540 (2015).
 38. Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol, https://doi.org/10.1038/
s41580-018-0003-4 (2018).
 39. Ahmed, M. et al. Systematic characterization of autophagy-related genes during the adipocyte differentiation using public-access 
data. Oncotarget 9, 15526–15541, https://doi.org/10.18632/oncotarget.24506 (2018).
 40. Baerga, R., Zhang, Y., Chen, P. H., Goldman, S. & Jin, S. Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a 
cellular model and in mice. Autophagy 5, 1118–1130 (2009).
 41. Zhang, Y. et al. Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesis. Proc Natl Acad 
Sci USA 106, 19860–19865, https://doi.org/10.1073/pnas.0906048106 (2009).
 42. Ro, S. H. et al. Distinct functions of Ulk1 and Ulk2 in the regulation of lipid metabolism in adipocytes. Autophagy 9, 2103–2114, 
https://doi.org/10.4161/auto.26563 (2013).
 43. Dadson, P. et al. Brown adipose tissue lipid metabolism in morbid obesity: Effect of bariatric surgery-induced weight loss. Diabetes 
Obes Metab 20, 1280–1288, https://doi.org/10.1111/dom.13233 (2018).
 44. Rui, L. B. and Beige Adipose Tissues in Health and Disease. Compr Physiol 7, 1281–1306, https://doi.org/10.1002/cphy.c170001 
(2017).
 45. Ro, S. H. et al. Sestrin2 inhibits uncoupling protein 1 expression through suppressing reactive oxygen species. Proc Natl Acad Sci 
USA 111, 7849–7854, https://doi.org/10.1073/pnas.1401787111 (2014).
 46. Huang, Y. C., Yu, H. S. & Chai, C. Y. Roles of oxidative stress and the ERK1/2, PTEN and p70S6K signaling pathways in arsenite-
induced autophagy. Toxicol Lett 239, 172–181, https://doi.org/10.1016/j.toxlet.2015.09.022 (2015).
 47. Budanov, A. V. & Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451–460, 
https://doi.org/10.1016/j.cell.2008.06.028 (2008).
 48. Lee, J. H. et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab 16, 311–321, https://doi.org/10.1016/j.
cmet.2012.08.004 (2012).
 49. Yu, H. S., Lee, C. H., Jee, S. H., Ho, C. K. & Guo, Y. L. Environmental and occupational skin diseases in Taiwan. J Dermatol 28, 
628–631 (2001).
 50. Lee, C. H. & Yu, H. S. Role of mitochondria, ROS, and DNA damage in arsenic induced carcinogenesis. Front Biosci (Schol Ed) 8, 
312–320 (2016).
 51. Maull, E. A. et al. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. 
Environ Health Perspect 120, 1658–1670, https://doi.org/10.1289/ehp.1104579 (2012).
 52. Huerta-Olvera, S. G. et al. Alpha-lipoic acid regulates heme oxygenase gene expression and nuclear Nrf2 activation as a mechanism 
of protection against arsenic exposure in HepG2 cells. Environ Toxicol Pharmacol 29, 144–149, https://doi.org/10.1016/j.
etap.2009.12.004 (2010).
 53. Snow, E. T., Sykora, P., Durham, T. R. & Klein, C. B. Arsenic, mode of action at biologically plausible low doses: what are the 
implications for low dose cancer risk? Toxicol Appl Pharmacol 207, 557–564, https://doi.org/10.1016/j.taap.2005.01.048 (2005).
 54. Lee, C. H. et al. Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers. Am J Pathol 
178, 2066–2076, https://doi.org/10.1016/j.ajpath.2011.01.056 (2011).
 55. Ro, S. H., Semple, I., Ho, A., Park, H. W. & Lee, J. H. Sestrin2, a Regulator of Thermogenesis and Mitohormesis in Brown Adipose 
Tissue. Front Endocrinol (Lausanne) 6, 114, https://doi.org/10.3389/fendo.2015.00114 (2015).
 56. Lago, C. U. et al. Mitochondrial respiratory uncoupling promotes keratinocyte differentiation and blocks skin carcinogenesis. 
Oncogene 31, 4725–4731, https://doi.org/10.1038/onc.2011.630 (2012).
 57. Kosnett, M. J. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol 9, 347–354, https://doi.
org/10.1007/s13181-013-0344-5 (2013).
 58. Zhang, H. N. et al. Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic. Proc Natl 
Acad Sci USA 112, 15084–15089, https://doi.org/10.1073/pnas.1521316112 (2015).
 59. Bessho, M. et al. Rho-kinase inhibitor Y-27632 attenuates arsenic trioxide toxicity in H9c2 cardiomyoblastoma cells. Cardiovasc 
Toxicol 13, 267–277, https://doi.org/10.1007/s12012-013-9206-2 (2013).
 60. Pucer, A. et al. Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human 
glioblastoma cells. Biol Chem 391, 519–531, https://doi.org/10.1515/BC.2010.050 (2010).
 61. Qi, Y. et al. Autophagy in arsenic carcinogenesis. Exp Toxicol Pathol 66, 163–168, https://doi.org/10.1016/j.etp.2014.01.004 (2014).
 62. Azad, M. B., Chen, Y. & Gibson, S. B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression 
and treatment. Antioxid Redox Signal 11, 777–790, https://doi.org/10.1089/ARS.2008.2270 (2009).
 63. Lau, A. et al. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol Cell Biol 33, 
2436–2446, https://doi.org/10.1128/MCB.01748-12 (2013).
 64. Komatsu, M. et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through 
inactivation of Keap1. Nat Cell Biol 12, 213–223, https://doi.org/10.1038/ncb2021 (2010).
13Scientific RepoRtS |         (2019) 9:14464  | https://doi.org/10.1038/s41598-019-50965-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
 65. Takamura, A. et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25, 795–800, https://doi.org/10.1101/
gad.2016211 (2011).
 66. Lahiri, P. et al. p62/Sequestosome-1 Is Indispensable for Maturation and Stabilization of Mallory-Denk Bodies. PLoS One 11, 
e0161083, https://doi.org/10.1371/journal.pone.0161083 (2016).
 67. Hanada, T. et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J Biol Chem 282, 
37298–37302, https://doi.org/10.1074/jbc.C700195200 (2007).
 68. Ichimura, Y. et al. In vivo and in vitro reconstitution of Atg8 conjugation essential for autophagy. J Biol Chem 279, 40584–40592, 
https://doi.org/10.1074/jbc.M405860200 (2004).
 69. Nakatogawa, H., Ichimura, Y. & Ohsumi, Y. Atg8, a ubiquitin-like protein required for autophagosome formation, mediates 
membrane tethering and hemifusion. Cell 130, 165–178, https://doi.org/10.1016/j.cell.2007.05.021 (2007).
 70. Gao, M., Li, C., Xu, M., Liu, Y. & Liu, S. LncRNA UCA1 attenuates autophagy-dependent cell death through blocking autophagic 
flux under arsenic stress. Toxicol Lett 284, 195–204, https://doi.org/10.1016/j.toxlet.2017.12.009 (2018).
 71. Ro, S. H. et al. Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281, 3816–3827, 
https://doi.org/10.1111/febs.12905 (2014).
 72. Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R. & Kroemer, G. Pharmacological modulation of autophagy: therapeutic 
potential and persisting obstacles. Nat Rev Drug Discov 16, 487–511, https://doi.org/10.1038/nrd.2017.22 (2017).
 73. Dodson, M. et al. Increased O-GlcNAcylation of SNAP29 drives arsenic-induced autophagic dysfunction. Mol Cell Biol, https://doi.
org/10.1128/MCB.00595-17 (2018).
 74. Zeinvand-Lorestani, M. et al. Autophagy upregulation as a possible mechanism of arsenic induced diabetes. Sci Rep 8, 11960, https://
doi.org/10.1038/s41598-018-30439-0 (2018).
 75. Cuervo, A. M., Knecht, E., Terlecky, S. R. & Dice, J. F. Activation of a selective pathway of lysosomal proteolysis in rat liver by 
prolonged starvation. Am J Physiol 269, C1200–1208, https://doi.org/10.1152/ajpcell.1995.269.5.C1200 (1995).
 76. Kiffin, R., Christian, C., Knecht, E. & Cuervo, A. M. Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol 
Cell 15, 4829–4840, https://doi.org/10.1091/mbc.e04-06-0477 (2004).
 77. Kaushik, S., Massey, A. C., Mizushima, N. & Cuervo, A. M. Constitutive activation of chaperone-mediated autophagy in cells with 
impaired macroautophagy. Mol Biol Cell 19, 2179–2192, https://doi.org/10.1091/mbc.E07-11-1155 (2008).
 78. Klein, J., Fasshauer, M., Klein, H. H., Benito, M. & Kahn, C. R. Novel adipocyte lines from brown fat: a model system for the study 
of differentiation, energy metabolism, and insulin action. Bioessays 24, 382–388, https://doi.org/10.1002/bies.10058 (2002).
 79. Bae, J. et al. Activation of pattern recognition receptors in brown adipocytes induces inflammation and suppresses uncoupling 
protein 1 expression and mitochondrial respiration. Am J Physiol Cell Physiol 306, C918–930, https://doi.org/10.1152/
ajpcell.00249.2013 (2014).
 80. Fontaine, D. A. & Davis, D. B. Attention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International 
Knockout Mouse Consortium. Diabetes 65, 25–33, https://doi.org/10.2337/db15-0982 (2016).
 81. Drobna, Z. et al. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for 
methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol 22, 1713–1720, 
https://doi.org/10.1021/tx900179r (2009).
 82. Hughes, M. F., Kenyon, E. M., Edwards, B. C., Mitchell, C. T. & Thomas, D. J. Strain-dependent disposition of inorganic arsenic in 
the mouse. Toxicology 137, 95–108 (1999).
 83. Kenyon, E. M., Del Razo, L. M. & Hughes, M. F. Tissue distribution and urinary excretion of inorganic arsenic and its methylated 
metabolites in mice following acute oral administration of arsenate. Toxicol Sci 85, 468–475, https://doi.org/10.1093/toxsci/kfi107 
(2005).
 84. Hughes, M. F., Menache, M. & Thompson, D. J. Dose-dependent disposition of sodium arsenate in mice following acute oral 
exposure. Fundam Appl Toxicol 22, 80–89 (1994).
 85. Sanchez-Pena, L. C. et al. Arsenic species, AS3MT amount, and AS3MT gene expression in different brain regions of mouse exposed 
to arsenite. Environ Res 110, 428–434, https://doi.org/10.1016/j.envres.2010.01.007 (2010).
 86. Torres-Avila, M., Leal-Galicia, P., Sanchez-Pena, L. C., Del Razo, L. M. & Gonsebatt, M. E. Arsenite induces aquaglyceroporin 9 
expression in murine livers. Environ Res 110, 443–447, https://doi.org/10.1016/j.envres.2009.08.009 (2010).
 87. Garcia-Montalvo, E. A., Valenzuela, O. L., Sanchez-Pena, L. C., Albores, A. & Del Razo, L. M. Dose-dependent urinary phenotype 
of inorganic arsenic methylation in mice with a focus on trivalent methylated metabolites. Toxicol Mech Methods 21, 649–655, 
https://doi.org/10.3109/15376516.2011.603765 (2011).
 88. Rodriguez, V. M. et al. Glutathione reductase inhibition and methylated arsenic distribution in Cd1 mice brain and liver. Toxicol Sci 
84, 157–166, https://doi.org/10.1093/toxsci/kfi057 (2005).
Acknowledgements
We thank Drs J. Klein (University of Lubeck, Germany), P. Black, C. DiRusso, J. Lee, O. Khalimonchuk, X. Sun, 
J. Lim, J. Zempleni, S. Chung (University of Nebraska-Lincoln, UNL), J. Barycki, and M. Simpson (UNL and 
North Carolina State University) for sharing cell lines, reagents and access to lab equipment. We thank Ro lab 
members for technical assistance and helpful discussion. We are grateful to Dr. S. Alvarez from Proteomics and 
Metabolomics core, Dr. Y. Zhou from Microscopy core, Dr. B. Brodersen and staff from Veterinary Diagnostics 
Center, and Dr. Y. Wang and staff from Biomedical and Obesity Research Core at UNL. This research was 
supported by Undergraduate Creative Activities and Research Experience (UCARE) program-scholarship 
from the Pepsi Quasi Endowment and Union Bank & Trust to K. Mahato and C. Schaecher, University of 
Nebraska ARD/ORED/BIOC grants, Layman awards, Nebraska Tobacco Settlement-Biomedical research 
enhancement funds and Nebraska Center for the Prevention of Obesity Diseases (NPOD) seed grant from NIH 
(P20GM104320) to S.-H. Ro.
Author contributions
J.B., Y.J., H.K. and S.-H.R. conceived the experiments, J.B., H.K., K.M., C.S. and E.K. performed cell culture 
experiments. Y.J., H.K. and I.K. performed mouse experiments. J.B., Y.J., H.K. and S.-H.R. prepared the 
manuscript. S.-H.R. developed and directed the research project. All authors discussed the experimental results 
and reviewed the manuscript.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50965-9.
Competing Interests: The authors declare no competing interests.
1 4Scientific RepoRtS |         (2019) 9:14464  | https://doi.org/10.1038/s41598-019-50965-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
